Fairmount Funds Management LLC - 17 Jun 2025 Form 4 Insider Report for Apogee Therapeutics, Inc. (APGE)

Role
Director
Signature
/s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC
Issuer symbol
APGE
Transactions as of
17 Jun 2025
Net transactions value
$0
Form type
4
Filing time
20 Jun 2025, 20:06:44 UTC
Previous filing
23 Jun 2025
Next filing
23 Jun 2025
SEC
View on sec.gov

Reporting Owners (3)

Name Relationship Address Signature Signature date CIK
Fairmount Funds Management LLC Director 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN /s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC 20 Jun 2025 0001802528
Kiselak Tomas Director 2001 MARKET STREET, SUITE 2500, PHILADELPHIA /s/ Tomas Kiselak 20 Jun 2025 0001830177
Harwin Peter Evan Director 2001 MARKET STREET, SUITE 2500, PHILADELPHIA /s/ Peter Harwin 20 Jun 2025 0001663607

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APGE Stock Option (Right to Buy) Award $0 +14,461 $0.000000 14,461 17 Jun 2025 Common Stock 14,461 $41.66 By: Peter Harwin F1, F2
transaction APGE Stock Option (Right to Buy) Award $0 +14,461 $0.000000 14,461 17 Jun 2025 Common Stock 14,461 $41.66 By: Tomas Kiselak F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents the right to purchase 14,461 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.
F2 Under Mr. Harwin's arrangement with Fairmount Funds Management LLC ('Fairmount'), Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.
F3 Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak holds the option for one or more Fairmount Funds. Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.

Remarks:

Fairmount may be deemed a director by deputization of Issuer by virtue of the fact that each of Peter Harwin and Tomas Kiselak serve on the board of directors of Issuer and are also each a Managing Member of Fairmount.